New Funding Secured for HEALEY ALS Platform Trial
Released
Released
Announcement PDF
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222
New Funding Secured for HEALEY ALS Platform Trial Participation
Not for release to US wire services or distribution in the United States
Highlights:
• Firm commitments to raise ~$7.1 million from existing shareholders and new sophisticated and professional
investors via a placement at $0.08 per Share – includes commitments from Directors and Management
totalling ~$0.8 million (subject to shareholder approval), demonstrating strong alignment with shareholders
and confidence in the Company’s strategy
• 2-for-5 pro rata non-renounceable entitlement offer to Eligible Shareholders to raise up to ~$17.1 million
• $20 million strategic convertible note facility established with New York-based Obsidian Global GP, LLC,
providing flexible, milestone-aligned funding over 2 years, minimising upfront dilution
• New funding underpins full execution of the HEALEY ALS Platform Trial and covers both the Randomised
Clinical Trial and Active Treatment Extension phases
• Additional funds to be deployed towards confirming broader platform potential for NUZ-001 across other
neurodegenerative diseases
• Strengthened balance sheet and extended capital runway, positioning Neurizon to pursue accelerated global
regulatory approval pathways, regional and worldwide partnering initiatives and broader commercial
opportunities for NUZ-001
• This is a timely and pivotal achievement for NUZ-001 as the Company prepares to dose its first patient in the
HEALEY ALS Platform Trial early in Q1 CY2026
23 December 2025 – Melbourne, Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA: OTCQB: NUZTF)
(“Neurizon” or the “Company”), a clinical-stage biotech company dedicated to advancing innovative treatments for
neurodegenerative diseases, is pleased to announce it has secured adequate funding for the Company’s
participation in the HEALEY ALS Platform Trial, an adaptive pivotal registration Phase 2/3 clinical trial for its lead
asset, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (“ALS”), the most common form of motor
neurone disease (“MND”).
The total funding package includes firm commitments from new and existing sophisticated and professional
investors to raise ~$7.1 million through the issue of ~89.1 million new fully paid ordinary shares (”Shares”) at an
issue price of $0.08 per Share (the “Placement”), as well as a $20 million strategic funding facility from New York-
based investment manager, Obsidian Global GP, LLC (”Obsidian” or “Investor”). Additionally, Neurizon will conduct
a 2-for-5 pro rata non-renounceable entitlement offer (“Entitlement Offer”) to Eligible Shareholders to raise up to
~$17.1 million.
This funding package, together with existing cash reserves and future AusIndustry R&D tax rebates, will fund the
Company’s participation in the HEALEY ALS Platform Trial (ClinicalTrials.gov identifier: NCT04297683). The HEALEY
ALS Platform Trial is a multicentre, double-blind, placebo-controlled, adaptive Phase 2/3 trial for ALS created in
partnership with the Network of Excellence for ALS (“NEALS”). The trial consists of 2 phases, a Randomised Clinical
Trial (RCT) phase and an Active Treatment Extension (ATE) phase, both of 36 weeks in duration. The goal of the
HEALEY ALS Platform Trial is to accelerate the development of potential new ALS therapies, including Neurizon’s
lead asset, NUZ-001. The trial tests and evaluates multiple investigational drugs simultaneously, shares
infrastructure across trial sites, and improves start-up and enrolment efficiencies, accelerating delivery of trial
results.
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222
Any additional capital raised through the Entitlement Offer will be used for working capital purposes, including
ongoing pre-clinical initiatives associated with Neurizon’s broader goal to leverage NUZ-001 as a platform molecule
for innovation and treatment across a range of neurodegenerative diseases, including Huntington’s Disease and
Frontotemporal Dementia (FTD), amongst others.
Managing Director and Chief Executive Officer, Dr Michael Thurn said: “This funding package fundamentally
transforms Neurizon’s position and reflects the market’s recognition of NUZ-001 as a Phase 3-ready asset of
international significance. Participation in the HEALEY ALS Platform Trial places NUZ-001 at the centre of the most
important and efficient clinical development framework for ALS treatment solutions globally, alongside programs
backed by leading academic institutions, regulators and industry.
Following the Company’s recent announcement of acceptance into the HEALEY ALS Platform Trial as Regimen I,
NUZ-001 has reached a significant inflection point in its clinical development. The injection of capital ensures we
are adequately funded to execute the HEALEY ALS Platform Trial, enabling Neurizon to further evaluate the
promising safety and early efficacy signals observed to date in a larger clinical setting, while also advancing
commercial, partnering and broader platform opportunities for NUZ-001 across multiple neurodegenerative
diseases.
Importantly, the structure of this funding, which combines new sophisticated and professional investors and
existing shareholder support, director alignment and a strategically flexible facility from Obsidian provides Neurizon
with the balance sheet strength to pursue value-maximising outcomes rather than any future reactive financing
requirements.
We believe NUZ-001 represents a differentiated, late-stage clinical ALS asset, and this funding package enables us
to focus squarely on execution, data generation and accelerated global regulatory pathways, supporting the
creation of long-term shareholder value.”
Placement Details:
Neurizon has secured firm commitments to undertake a Placement to raise ~$7.1 million (before costs) through
the issue of ~89.1 million new Shares at $0.08 per Share (”Offer Price”). The Offer Price represents a 27.3% discount
to the last traded price of $0.11 per Share and a 27.3% discount to the 5-day volume weighted average price
(“VWAP”) of $0.11 per Share. The Placement includes commitments from Neurizon’s Board and Management
totalling $0.8 million, which will be subject to shareholder approval at an upcoming extraordinary general meeting.
$20 million Financing Facility from Obsidian:
As part of the funding package, the Company has entered into an agreement with New York-based investment
manager, Obsidian Global GP, LLC (“Obsidian” or the ”Investor”) to establish a convertible note facility which will
provide up to $20 million in aggregate funding over a two-year period from date of first purchase (the ”Convertible
Note Facility”).
Obsidian is a New York-based alternative investment firm with a strong track record of funding growth-stage
biotech companies listed on Nasdaq and ASX. Their structured investments are designed to align with a company’s
capital requirements and long-term vision, offering operational flexibility with minimal dilution.
The investment by Obsidian in Neurizon follows an extensive and considered review of funding options available to
the Company. Following a period of due diligence, the investment reflects Obsidian’s confidence in Neurizon’s lead
clinical asset and its potential to progress through accelerated regulatory pathways. The financing terms have been
structured to support Neurizon’s participation in the HEALEY ALS Platform Trial while maintaining financial
flexibility.
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222
The Convertible Note Facility has been deliberately structured to allow Neurizon to draw capital progressively,
aligning funding access with clinical and regulatory milestones while minimising unnecessary dilution for
shareholders and option holders.
Importantly, the facility preserves the Company’s ability to actively pursue alternative sources of funding, including
non-dilutive grant funding, regional licensing and partnering deals, rather than requiring full utilisation of the facility
upfront. This optionality enables Neurizon to optimise its capital structure as the clinical program matures and
additional value inflection points are achieved.
The Board considers the Convertible Note Facility to be an efficient and pragmatic funding solution that supports
execution certainty while maintaining balance sheet discipline. The structure provides funding certainty over two
years, ensures the Company remains well-capitalised to deliver its near-term objectives, and positions Neurizon to
maximise long-term shareholder and option holder value as the HEALEY ALS Platform Trial progresses.
The initial drawdown under the Convertible Note Facility will be $5m. The Convertible Note Facility is subject to a
number of conditions, including shareholder approval.
The terms of the Convertible Note Facility will require the Company to initially place 10,000,000 Shares with the
Investor, to be paid for by the Investor during the term of the Convertible Note Facility, or to be set off against the
Company’s obligation to issue shares under the Convertible Note Facility and with any Shares still held by the
Investor, at the time when the Convertible Note Facility has ended and there are no Convertible Notes on issue, to
either be acquired by the Investor or sold and the proceeds remitted to the Company. A further 15,000,000 Shares
may be issued over the term of the agreement, subject to certain conditions being satisfied, and on the terms
described above. The issue of the 10,000,000 shares will be subject to shareholder approval at an upcoming general
meeting. The Company has also entered into a general security agreement with Obsidian in respect of the
Convertible Note Facility.
A summary of the key terms of the Convertible Note Facility is annexed to this release.
Entitlement Offer Details:
Neurizon intends to undertake a pro-rata non-renounceable entitlement offer to raise up to ~$17.1 million (before
costs), under which eligible shareholders will be offered the opportunity to acquire 2 new Shares for every 5 Shares
held as at 7.00pm on Tuesday, 30 December 2025 (“Record Date”) at an Offer Price of $0.08 per new Share (being
the same Offer Price as that under the Placement).
The Entitlement Offer is open to “Eligible Shareholders” being persons who:
• are registered as a holder of Shares as at the Record Date, being 7.00pm (AEDT) on Tuesday, 30 December
2025;
• as at the Record Date, have a registered address on the Neurizon share register in Australia or New Zealand
(or did not have a registered address in Australia or New Zealand but Neurizon has otherwise determined
is eligible to participate);
• are not in the United States and are not acting for the account or benefit of persons in the United States;
and
• are eligible under all applicable securities laws to receive an offer under the Entitlement Offer without any
requirement for a prospectus or offer document to be lodged or registered.
Eligible Shareholders who take up their entitlement in full may apply for additional new Shares under the
Oversubscription Facility (“Oversubscription Facility”). Additional new Shares will only be available under the
Oversubscription Facility to the extent that there is any shortfall under the Entitlement Offer. The allocation of
additional New Shares will be at the discretion of Neurizon and may be subject to scale back.
In the event there remains a shortfall following the issue of any additional New Shares under the Oversubscription
Facility, any remaining shortfall may be placed within 3 months following the close of the Entitlement Offer at the
discretion of the Board.
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222
The Entitlement Offer is non-renounceable, meaning that Eligible Shareholders will not be able to transfer their
entitlements pursuant to the Entitlement Offer and if they do not subscribe for their entitlements pursuant to the
Entitlement Offer, their shareholding in Neurizon will be diluted.
All new Shares issued pursuant to the Entitlement Offer and Placement will rank equally with the existing Shares
on issue from the date of allotment.
Full details of the Entitlement Offer, including the timetable and details for how to accept the Entitlement Offer,
will be set out in an offer booklet (“Offer Booklet”), which Neurizon will lodge with the ASX and dispatch to Eligible
Shareholders on or around Monday, 5 January 2026. Eligible Shareholders should read the Offer Booklet in its
entirety and consult with their stockbroker, accountant or other professional adviser before making any decision
as to whether to subscribe for any new Shares.
Indicative Timetable:
INDICATIVE OFFER TIMETABLE
Event Dates (AEDT)
Trading Halt Friday, 19 December 2025
Trading Halt Lifted and Return to Trading on the ASX, Announce Results of Placement,
Announce Entitlement Offer
Tuesday, 23 December 2025
Entitlement Offer ‘Ex” date Monday, 29 December 2025
Entitlement Offer Record Date Tuesday, 30 December 2025
Placement Settlement Date Wednesday, 31 December 2025
Placement Allotment Date Friday, 2 January 2026
Entitlement Offer Documents Dispatched to Eligible Shareholders, Entitlement Offer Opening
Date
Monday, 5 January 2026
Last day to Extend the Entitlement offer Closing Date Before noon, Friday 16 January 2026
Entitlement Offer Closing Date 5.00pm, Wednesday, 21 January 2026
Securities Quoted on a Deferred Settlement Basis from Market Open Thursday, 22 January 2026
Announce Results of Entitlement Offer Tuesday, 27 January 2026
Entitlement Offer Settlement Date Wednesday, 28 January 2026
Entitlement Offer Allotment Date Thursday, 29 January 2026
Commencement of Trading of New Shares Issued under the Entitlement Offer on ASX Friday, 30 January 2026
Dispatch of Holding Statements for New Shares issued under the Entitlement Offer Friday, 30 January 2026
General Meeting to approve Director and Management Placement Participation and
Convertible Note Facility
Expected February 2026
The above timetable is indicative only and may be subject to change at the sole discretion of the Company, in
consultation with the Lead Manager, in compliance with the ASX Listing Rules and Corporations Act 2001 (Cth)
(“Corporations Act”).
Additional Information:
Additional Information in relation to the Placement, Entitlement Offer and Convertible Note Facility can be found
in the investor presentation to be lodged on the ASX today (“Investor Presentation”). An Offer Booklet with further
details in respect of participating in the Entitlement Offer will be lodged with the ASX and dispatched to Eligible
Shareholders on or around Monday, 5 January 2026. These documents contain important information including
key risks in respect of an investment in Neurizon. This announcement does not constitute an offer to issue or sell,
or a solicitation of an offer to subscribe or buy securities in any jurisdiction where such an offer or sale would be
unlawful.
The Entitlement Offer will be made under section 708AA of the Corporations Act (as modified). Investors should
seek appropriate professional advice before making any investment decision.
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222
Morgans Corporate Limited is acting as placement agent (in respect of the Placement) and lead manager and
bookrunner (in respect of the Entitlement Offer) (“Lead Manager”).
Compliance Statement in Respect of the Convertible Note Facility and Convertible Notes to be Issued Under it:
The Company provides the following information for the purposes of section 4 of ASX Compliance Update No 05/20,
and ASX Compliance Update No 05/23:
• the Company has negotiated the convertible notes at arm’s length with a sophisticated and professional
investor who is an independent third party to the Company;
• the Company considers that the issue of the convertible notes is an appropriate and commercial solution to
provide working capital to enable to Company to support its ongoing exploration activities and operations;
• prior to entering into the Convertible Note Facility agreement, the Company considered other available fund-
raising options, such as a traditional equity raising and other types of equity-linked debt instruments, to meet
the Company’s funding requirements. The Company was of the view that the other options available were not
on the same commercial terms and were therefore not in the best interests of shareholders of the Company;
and
• the Company has agreed to both enter into a general security agreement and to issue Placement Shares to
Obsidian. The reason why the Placement Shares are being issued in addition to the grant of security under the
general security agreement is that the Placement Shares are intended to be available to be used to offset any
future Shares issued to Obsidian (at its discretion) in the event of conversion of the convertible notes.
The Company confirms that it sought legal advice from a suitably qualified and experienced lawyer regarding the
suitability of the terms of the convertible notes and was advised that the convertible notes were market standard
and do not contain any of the features noted in section 5.9 of ASX Guidance Note 21, based on the reasons set
out below:
• conversion of the convertible notes is either at a fixed price or at a price based on the market price for Shares
and not some other variable;
• the convertible notes convert into ordinary shares in the company and not into other convertible securities;
and
• there are other convertible notes on similar terms in the market.
-ENDS-
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222
This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.
For further information, please contact:
Neurizon Therapeutics
Lidija Damjanovic
Marketing & Corporate Affairs
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504
Australia Investor Relations
Henry Jordan
Six Degrees Investor Relations
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538
U.S. Investor Relations
Matthew Selinger
Integrous Communications
Email: mselinger@integcom.us
Phone: +1 415-572-8152
Not an offer of securities
This announcement has been prepared for publication in Australia and may not be released to US wire services or
distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer
to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have
not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the
United States except in transactions exempt from, or not subject to, the registration requirements of the US
Securities Act and applicable US state securities laws.
About Neurizon Therapeutics Limited
Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing
treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the
treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate
access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader
neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is
dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an
investigational product and is not approved for commercial use in any jurisdiction.
Neurizon Investor Hub
We encourage you to utilise our Investor Hub for any enquiries regarding this
announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and
view video summaries of key announcements.
To access Neurizon Investor Hub please scan the QR code or visit
https://investorhub.neurizon.com
Neurizon® is a registered trademark of Neurizon Therapeutics Limited.
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222
Annexure A – Summary of key terms of Convertible Note Facility
Convertible Note
Facility
The Company may create and issue convertible notes convertible into Shares (“Convertible Notes”). The Investor
agrees to subscribe for the Convertible Notes in accordance with the Convertible Note Facility.
Facility for up to A$20 million (“Commitment Limit”).
On each “Purchase Date” (set out below) the Investor must pay the Company the relevant “Purchase Price” (set out
below) and the Company must issue the relevant number of Convertible Notes, each a “Purchase”:
• First Purchase: A$5 million within 5 business days after the Company obtains shareholder approval (and
any other regulatory approvals required) to the issue of the Convertible Notes;
• Subsequent Purchases: between A$2.5 million to A$5 million at Neurizon’s discretion, or such other
amount as agreed between the parties, subject to an overall limit of the Commitment Limit, at times
agreed between the Company and Investor, provided that: (i) the first Subsequent Purchase cannot
occur prior to 1 September 2026; (ii) a Subsequent Purchase cannot occur less than 6 months after a
preceding Subsequent Purchase; (iii) no Subsequent Purchase can occur after the date which is 24
months after the date of the First Purchase. In respect of the First Subsequent Purchase, the Company
must have a cash balance of at least A$9.5 million immediately prior to the First Subsequent Purchase.
The Company will issue the Investor the number of Convertible Notes which is the same as the number which is the
actual amount paid in US$ (converted at the exchange rate agreed by the parties) by the Investor so as to procure
the transfer of the relevant Purchase Price to the Company, rounded upwards to the nearest whole number.
Placement Shares Subject to receipt of Company shareholder approval, the Company must issue 10 million Shares to the Investor on
or before the Purchase Date of the First Purchase, and may be obliged to issue a further 15 million Shares during
the term of the Convertible Note Facility (“Placement Shares”).
Subject to receipt of Company shareholder approval, the Company will be obliged to issue some or all of the
further 15 million Placement Shares to the Investor at the times and in the amounts requested by the Investor,
provided that the Investor will only be entitled to make a request:
• following an event of default (set out below); or
• where the market value of the aggregate number of Placement Shares issued to the Investor (as
determined by multiplying the aggregate number of Placement Shares by the daily VWAP for the actual
trading day immediately prior to the date of the request) is less than A$500,000, and in that event, the
Investor may only request the issue of such number of Placement Shares which would result in the market
value of the aggregate number of Placement Shares issued to the Investor equaling A$1,000,000.
The Investor may reduce the aggregate number of Placement Shares by a number of shares by notifying the
Company and paying the Company for the relevant number of Shares, the price being the amount equal to the
number of shares multiplied by 94% of the average of the lowest 5 daily VWAPs during the 20 actual trading days
prior to the date of the notice, rounded to the nearest A$0.0001.
During the term of the Convertible Note Facility, at any time the Company is required to issue Shares to the
Investor upon the conversion of a Convertible Note, the Investor may elect to partially or wholly satisfy the
Company's obligation to issue those Shares by reducing the aggregate number of Placement Shares by the
corresponding number of Shares to be issued to the Investor upon the Conversion.
If any number of Placement Shares remain outstanding following termination or expiry of the Convertible Note
Facility or full repayment of the Convertible Notes (“Payment Trigger”), the Investor must within 15 actual trading
days of Shares (“Payment Period”) either (at the Company’s election): (i) sell the Placement Shares on market and
pay 100% of the net sale proceeds to the Company; or (ii) transfer the Placement Shares to the Company’s nominee
for no consideration, provided that, if the Payment Period has not completed by the date which is 60 days after the
Payment Trigger, then the Investor must comply with option (ii) above.
Security The Convertible Note Facility is to be secured by a general security agreement over the Company’s assets (“Security
Document”).
Face Value US$1.11 per Convertible Note (“Face Value”).
If an Unremedied Default (set out below) occurs, the Face Value of all outstanding Convertible Notes will
automatically increase by 5% in the first instance and afterward by an additional 1% for any further Unremedied
Default.
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222
Interest No interest is payable on the Convertible Notes.
If the Company fails to pay or repay any amount payable under the Convertible Note Facility when due, or any
other event of default occurs, interest shall be payable on the relevant amount (on in the case of an event of
default, on the amounts outstanding on the Notes) at a rate of 10% per annum, which interest shall accrue daily
and shall be compounded monthly, from the date when the relevant amount payable was due, or the date of the
event of default (as the case may be), until the Company pays that amount payable, or until the Company pays the
amounts outstanding or otherwise remedies the event of default (as the case may be).
Maturity In respect of Convertible Notes issued at a particular Purchase, the relevant Convertible Notes will mature 36
months after the relevant Purchase (“Maturity Date”).
Conversion prices The Investor may convert one or more Convertible Notes on issue to them at any time at:
• in respect of:
o Convertible Notes issued at the First Purchase: A$0.165;
o Convertible Notes issued at a Subsequent Purchase: 150% of the 5 day VWAP for the 5 actual
trading days of Shares immediately prior to the date on which the Subsequent Purchase
occurs,
(the “Fixed Conversion Price”); or
• subject to the limitations on conversions (set out below), a price of 94% of the average of the 5 lowest
daily VWAPs during the 20 actual trading days of Shares prior to the conversion notice date rounded to
the nearest A$0.0001 (the “Variable Conversion Price”).
See also “Effect of event of default” set out below.
Limitations on
conversions
Unless an event of default occurs, the Investor may only give conversion notices specifying that a conversion of
Convertible Notes is to occur at the Variable Conversion Price as and from the day which is 60 days after the
Purchase of those Convertible Notes.
The Investor must not give a conversion notice where the issue of Shares under that conversion notice would cause
the Investor to hold more than 9.99% of all Shares on issue at the relevant time.
Trading restrictions The Investor agrees not on any trading day to sell Shares in excess of the greater of: (i) 20% of the daily trading
volume on that trading day on ASX and Chi-X (as reported by IRESS); and (ii) a value of A$50,000.
The requirements and restrictions above will cease to apply if: (i) there is any event of default; or (ii) the daily
VWAP does not exceed a predetermined threshold for any 10 consecutive actual trading days of Shares, provided
that, for the avoidance of doubt, at all times the Investor must comply with Part 7.10 of the Corporations Act
The Investor is also restrained from short selling.
Inability to issue
Shares
If a conversion notice is issued in respect of a Convertible Note by the Investor at a time when Shares are unable to
be issued by the Company, the Investor shall have the option to: (i) cancel the relevant conversion notice; or, if the
Company remains unable to issue the Shares after 60 days (ii) give notice to the Company requiring the Company
to redeem the relevant Convertible Notes at the greater of the value calculated using the daily VWAP for the actual
trading day immediately prior to the conversion notice date and the Redemption Amount (set out below).
Redemption • Unless an event of default occurs, the Company may at any time prior to the Maturity Date redeem
some or all of the outstanding Convertible Notes at 110% of the aggregate total of the Face Values of
the outstanding Convertible Notes to be redeemed (“Redemption Amount”) by giving notice to the
Investor (“Early Redemption Notice”).
• Subsequent to the Company giving an Early Redemption Notice, the Investor may freely give conversion
notices in respect of Convertible Notes the subject of an Early Redemption Notice, until the Company
pays the Redemption Amount in respect of those Convertible Notes.
• See also “Effect of event of default” set out below.
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222
Conditions
precedent
Conditions precedent in respect of each transaction contemplated in the Convertible Note Facility include:
• the ASX not advising the Company that it considers the terms of the Convertible Notes are not both
appropriate and equitable for the purposes of Listi
Share your feedback
Discover